Browse News
Filter News
Found 54 articles
-
Cell and Gene Therapy Market Size to Reach USD 97.33 Bn by 2033
4/5/2024
According to the latest research by nova one advisor, the global cell and gene therapy market size was valued at USD 18.13 billion in 2023 and is anticipated to reach around USD 97.33 billion by 2033, growing at a CAGR of 18.3% from 2024 to 2033.
-
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
2/29/2024
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.
-
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
1/22/2024
Apnimed, Inc. announced Graham Goodrich has joined the company as Chief Commercial Officer and Ted Harding as Chief Human Resources Officer.
-
The regulator greenlit 55 new drugs last year, seven of which belonged to Pfizer, including an ulcerative colitis treatment and a migraine nasal spray—both acquired in multibillion-dollar buys.
-
Patients treated with Xenon Pharmaceuticals’ investigational potassium channel opener XEN1101 experienced a significant and dose-dependent reduction in seizure frequency.
-
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
8/14/2023
NewAmsterdam Pharma Company N.V. announced the appointment of William “BJ” Jones as the Company’s first Chief Commercial Officer, effective August 14, 2023.
-
In its second-quarter earnings reported Tuesday, Pfizer announced total revenues declined 54% to $12.7 billion, primarily due to a plummet in Paxlovid and Comirnaty sales.
-
9 Top M&As in the First Half of 2023
6/28/2023
Despite a challenging economic climate and gloomy forecast, 2023 has still notched some mega-deals for biopharmas. BioSpace highlights the biggest deals in the industry this year. -
Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management
6/22/2023
Apogee Therapeutics announced the appointments of Jennifer Fox and William “BJ” Jones, seasoned executives in the biotechnology industry, to its board of directors.
-
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
5/12/2023
Biohaven Ltd. reported financial results for the first quarter ended March 31, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
-
The company’s pipeline changes come as it weathered a nearly 30% decline in first-quarter revenues due to a slowdown in its COVID-19 business.
-
Pfizer Reports First-Quarter 2023 Results
5/2/2023
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2023 and reaffirmed full-year 2023 financial guidance.
-
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
3/23/2023
Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today reported financial results for the fourth quarter ended December 31, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones.
-
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
2/28/2023
Revance Therapeutics, Inc., announced the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023.
-
Eliem Therapeutics is dropping a depression drug candidate and laying off 55% of staff in an attempt to stretch its cash runway to 2027.
-
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
1/31/2023
Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
-
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
1/9/2023
Ionis Pharmaceuticals, Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZA® and Novartis' pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments.
-
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
11/9/2022
Arrowhead Pharmaceuticals Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.
-
Pfizer Reports Strong Third-quarter 2022 Results and Raises 2022 Outlook
11/1/2022
Pfizer Inc. reported solid financial results for third-quarter 2022 and updated certain components of 2022 financial guidance.
-
Funding rounds this week saw money flow into innovative drug discovery and delivery platforms, while pharma powerhouse Pfizer wrapped up two high-value neuro deals.